Humana (HUM) has drawn fresh attention after recent trading, with the stock showing a mix of short term gains and longer term declines that raises questions about how investors currently view its valuation.

Recent trading has pushed Humana’s share price to $380.26, with a 30 day share price return of 24.63% and a 1 year total shareholder return of 64.10%. However, 3 and 5 year total shareholder returns remain in decline, suggesting momentum has recently picked up after a tougher multi year stretch.

If you want to see how other healthcare related opportunities are moving alongside Humana, this is a good moment to scan the market using our curated list of 39 healthcare AI stocks

So, with Humana stock up sharply in the past month but longer-term returns still lagging, is the current price signaling a genuine value gap, or is the market already factoring in future growth and leaving limited upside for new buyers?

Most Popular Narrative: 78.6% Overvalued

According to the most followed narrative on Humana, the fair value is set at $212.87, which sits well below the recent $380.26 share price and frames the recent rally as potentially stretched.

Humana’s current pressures underscore that reality. As Medicare Advantage continues to expand, the companies that thrive will likely be those that treat compliance not as a checkbox, but as an operational framework embedded into every layer of their billing and clinical review systems.

Want to understand why this narrative places such a gap between Humana’s fair value and its current price? The core assumptions rest on how margins evolve, how revenue growth moderates over time, and what kind of profitability profile investors are effectively paying for today. The full narrative spells out those moving parts in detail, including the implied future earnings multiple that underpins the $212.87 figure.

Result: Fair Value of $212.87 (OVERVALUED)

However, investors also have to consider risks to this Humana thesis, including potential shifts in Medicare rules or changes in audit intensity that could alter compliance costs.

Another View: Humana Stock Through a Market Multiple Lens

While the leading Humana narrative pegs fair value at $212.87 and labels the stock as overvalued, the market’s own yardstick paints a more mixed picture. At a P/E of 40.4x, Humana is below its estimated fair ratio of 42.3x, yet above the US Healthcare industry average of 23.4x and the peer average of 33.8x.

In practice, that means investors are paying a clear premium to the sector and peers, but not an extreme one relative to where the fair ratio suggests the P/E could settle. The tension is whether that premium signals crowding risk at $380.26, or represents a valuation that still leaves room if earnings evolve as expected.

Next Steps

If this mix of optimism and concern around Humana feels finely balanced, consider acting sooner rather than later. Test the numbers, assumptions, and sentiment against your own view by weighing up the 2 key rewards and 2 important warning signs

Looking for more investment ideas beyond Humana?

Humana gives you one perspective on healthcare, but your portfolio deserves a broader watchlist of opportunities that match your goals, risk comfort, and time horizon.

• Target higher potential upside by scanning a curated group of 23 elite penny stocks with strong financials that combine smaller size with stronger financial profiles than many peers.
• Strengthen your core portfolio by reviewing 47 high quality undervalued stocks that pair quality fundamentals with prices that may sit below their estimated worth.
• Reduce portfolio stress by focusing on 68 resilient stocks with low risk scores that score well on resilience, balance sheet strength, and business stability.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.